The EORTC phase III 26053-22054/ RTOG 0834/NCIC CTG CEC.1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas. The primary endpoint was overall survival.We report the results of retrospective individual case reviews (ICRs) for the first patient randomized per institution to detect the compliance with the study protocol.
from Imaging via alkiviadis.1961 on Inoreader http://bit.ly/2Ihb0n1
Πέμπτη 29 Μαρτίου 2018
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial “concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma”: Individual case review analysis
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018 Apr;287(1):11-28 Authors: Haller S, Vernooij MW, Kuij...
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Excerpt from Common Culture: Reading and Writing About American Popular Culture. Ed. Michael Petracca, Madeleine Sorapure. Upper Saddle Rive...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου